Cambridge Antibody Technology's Acquisition

Cambridge Antibody Technology was acquired by AstraZeneca on May 15, 2006.

Cambridge Antibody Technology is engaged in the development of human monoclonal antibodies as new treatments for disease, having developed a pipeline of human monoclonal antibodies. HUMIRA, an antibod…

Articles about Cambridge Antibody Technology's Acquisition: